Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > REGULATORY
REGULATORY
- “Politicians Should Not Intervene” in Dispute Over Rule to Reduce Medical Fees Claimed: Parliamentary Secretary of Health
February 18, 2014
- 34 Firms Win Approval for Diovan Generics, 31 for Preminent Generics towards June Listing
February 17, 2014
- Diet Begins Discussions on 2 Bills Related to Establishment of “Japanese NIH,” Aimed at Commercialization of Innovative New Drugs
February 17, 2014
- Joint Purchasing May Rise as Hospitals with Low Settlement Rates Face Cuts in Fees Claimed: Chuikyo Member
February 17, 2014
- Kaketsuken Makes Another Bid to Fill Unmet Flu Vaccine Quota for 25 Million People
February 14, 2014
- FY2014 Medical Fee Revision to Limit Premium for Atypical Antipsychotics to Prescriptions with 2 or Fewer Drugs
February 14, 2014
- FY2014 NHI Drug Pricing Reform – Part 4: “Precursor Premium” to Be Introduced, but Hurdle Will Be High; Prices of a Wider Range of New Products to Be Adjusted Based on Average Foreign Prices
February 14, 2014
- FY2014 NHI Drug Pricing Reform – Part 3: Full Introduction of Premium for New Drug Development Rejected Again
February 14, 2014
- PAFSC’s 1st Committee to Review Prasugrel, 3 Combination Antihypertensives on Feb. 24
February 13, 2014
- Upper Limit for Evaluating Rate of Generic Drug Use of DPC Hospitals to Be 60%: Chuikyo’s Recommendation for FY2014 Reform
February 13, 2014
- Prescription, Medication Fees Received for 30-Day or Longer Prescriptions to Be Reduced by 40% at Large Hospitals: FY2014 Medical Fee Reform
February 13, 2014
- Chuikyo Submits Recommendations for FY2014 Revision; Hospitals, Pharmacies with Low Settlement Rates to Face Fee Cuts of Up to 26％
February 12, 2014
- PMDA to Raise Face-to-Face Advising Fees in April
February 12, 2014
- Takeda, 9 Other Drug Makers Join Hands in US NIH Initiative to Quest for New AD, Diabetes, RA Medicines
February 10, 2014
- Chuikyo to Submit Recommendations for FY2014 Medical Fee Revision on Feb. 12
February 10, 2014
- Warning on Interstitial Pneumonia to Be Added to Precautions Section of Package Insert for Rivaroxaban
February 10, 2014
- Bill Payers, Healthcare Providers Agree to Increase Medical Fees, Dispensing Fees
February 7, 2014
- Regulatory Reform Council Selects “Switch-OTC In Vitro Diagnostics” as Target for “International Benchmark Test”
February 7, 2014
- FY2014 NHI Drug Pricing Reform –Part 1: New Rules Will Spur Efforts to Escape Dependence on Long-Listed Drugs, Spark Reorganization of Generic Industry
February 7, 2014
- FY2014 NHI Drug Pricing Reform –Part 2: Introduction of New Rule for Long-Listed Drugs, Elimination of Special Price Cuts Could Spark Shift to New Drugs, Use of AG Strategy
February 7, 2014
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…